Patents Assigned to AstraZeneca
  • NEW COMPOUNDS 835
    Publication number: 20090233943
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: May 14, 2008
    Publication date: September 17, 2009
    Applicants: Astex Therapeutics Limited, AstraZeneca AB
    Inventors: Jeremy Nicholas Burrows, Sven Hellberg, Katharina Hogdin, Sofia Karlstrom, Karin Kolmodin, Johan Lindstrom, Can Slivo
  • Inhaler device counter
    Patent number: 7587988
    Abstract: Inhaler counter (20) comprising a counter housing (390), a rocker arm (200) with a pawl (210), the rocker arm being pivotally supported by the housing and arranged to perform a rocker movement in response to a linear actuation motion, a return spring (220) for resetting the rocker arm, a ratchet wheel (230) engagable with the pawl to convert the movement of the rocker arm into an incremental rotational motion of an axle arrangement (240) advancing a display means (60), the axle arrangement further comprising a back rotation prevention means (280) in the form of a spring loaded friction brake and a worm gear, the display means comprising rotatable indicator means (120) with teeth that engage the worm-gear and a stationary scale.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: September 15, 2009
    Assignee: AstraZeneca AB
    Inventors: Nic Bowman, Douglas Bradshaw, Lennart Sörby
  • COMPOUNDS EFFECTING GLUCOKINASE
    Publication number: 20090227592
    Abstract: The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).
    Type: Application
    Filed: February 2, 2009
    Publication date: September 10, 2009
    Applicant: AstraZeneca AB
    Inventors: Scott BOYD, Peter William Rodney CAULKETT, Rodney Brian HARGREAVES, Suzanne Saxon BOWKER, Roger JAMES, Clifford David JONES, Darren McKERRECHER, Michael Howard BLOCK, Craig JOHNSTONE
  • Pteridine Derivatives and their Use as Cathespin Inhibitors
    Publication number: 20090227579
    Abstract: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin K.
    Type: Application
    Filed: June 20, 2007
    Publication date: September 10, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Robert Andrew Heald, Andrew David Morley
  • Novel Pyridine Compounds
    Publication number: 20090227555
    Abstract: The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: June 23, 2008
    Publication date: September 10, 2009
    Applicant: AstraZeneca AB
    Inventors: Peter Bach, Jonas Bostrom, Kay Brickmann, Leifeng Cheng, Fabrizio Giordanetto, Robert Groneberg, Darren Harvey, Michael O'Sullivan, Fredrik Zetterberg
  • SNPS IN THE APOB GENE AND SUSCEPTIBILITY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION
    Publication number: 20090227559
    Abstract: This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the apoB gene and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients.
    Type: Application
    Filed: October 3, 2006
    Publication date: September 10, 2009
    Applicant: AstraZeneca AB
    Inventors: Olof Bengtsson, Ellen Brown, Stefan Carlsson, Neil James Gibson, Ansar Jawaid, Andreas Kindmark, Ruth Eleanor March
  • Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one
    Patent number: 7585867
    Abstract: A compound of formula (I) and pharmaceutically acceptable salts or solvates thereof for use in therapy.
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: September 8, 2009
    Assignee: AstraZeneca AB
    Inventor: Roger Victor Bonnert
  • Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
    Patent number: 7585881
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: September 8, 2009
    Assignee: AstraZeneca AB
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tau Xin, Jalaj Arora
  • Compounds having selective inhibiting effect at GSK3
    Patent number: 7585853
    Abstract: The present invention relates to new compounds of formula (I) wherein: Z is N and X is CH or N; Y is CONR5; P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S; Q is phenyl or a 5 or 6 membered aromatic heterocyclic ring containing one or more nitrogen atoms; R is C1-6alkylNR10R11 or C1-6alkylazetidine; R10 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C0-6alkylC3-6cycloalkyl, C0-6alkylaryl, C0-61alkylheteroaryl or C1-6alkylNR8R9; R11 is C1-6alkylNR8R9, C0-6alkylC3-6cycloalkyl or C0-6alkylheterocycloalkyl; as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: September 8, 2009
    Assignee: AstraZeneca AB
    Inventors: Stefan Berg, Sven Hellberg, Peter Soderman
  • 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists
    Publication number: 20090221653
    Abstract: The present invention provides compounds of formula (I) wherein the variables are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: August 28, 2006
    Publication date: September 3, 2009
    Applicant: AstraZeneca AB
    Inventors: Andrew Bailey, Roger Bonnert, Stephen Connolly, Anthony Ingall, Garry Pairaudeau, Michael Stocks
  • Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts
    Publication number: 20090221576
    Abstract: New use of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base or a pharmaceutically acceptable salt thereof, in a method of prevention and/or treatment of bone-related disorders, osteoporosis, increasing bone formation or increasing bone mineral density.
    Type: Application
    Filed: January 31, 2007
    Publication date: September 3, 2009
    Applicant: ASTRAZENECA AB GLOBAL INTELLECTUAL PROPERTY
    Inventors: Anna-Lena Berg, Ratan Bhat
  • Novel Crystal Modifications
    Publication number: 20090221640
    Abstract: Novel crystal modifications of (5S)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonylmethyl]-5-methyl-imidazolidine-2,4-dione are disclosed together with processes for preparing such modifications, pharmaceutical compositions comprising such a modification, and the use of such a modification in therapy.
    Type: Application
    Filed: March 15, 2007
    Publication date: September 3, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Lars-Erik Briggner, Anders Eriksson, Neil Barnwell, Andrea Cole, Jacob Perkins, Luis-Manuel Vaz, Andrew Wells
  • MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177
    Publication number: 20090221567
    Abstract: Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein Y, X, A, R1, R2, m, p, and q are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: February 25, 2009
    Publication date: September 3, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Yun-Xing Cheng, Xuehong Luo, Mehrnaz Pourashraf, Vijayaratnam Santhakumar, Miroslaw Jerzy Tomaszewski
  • PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS
    Publication number: 20090221663
    Abstract: A compound of Formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are also described.
    Type: Application
    Filed: October 28, 2008
    Publication date: September 3, 2009
    Applicant: AstraZeneca AB
    Inventors: Martin John Packer, James Stewart Scott, Andrew Stocker, Paul Robert Owen Whittamore
  • MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF-176
    Publication number: 20090221642
    Abstract: Compounds of Formula 1, or pharmaceutically acceptable salts thereof: wherein X, R1, R2, R3, R4, R5, n, m, and p are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: February 25, 2009
    Publication date: September 3, 2009
    Applicant: AstraZeneca AB
    Inventors: Shujuan Jin, Miroslaw Jerzy Tomaszewski, Vijayaratnam Santhakumar
  • Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I
    Publication number: 20090221657
    Abstract: Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, R5, and G are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: May 15, 2009
    Publication date: September 3, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Daniel Page, Ziping Liu, Maxime Tremblay, Christopher Walpole, Hua Yang
  • NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471
    Publication number: 20090221660
    Abstract: New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are also described.
    Type: Application
    Filed: February 3, 2009
    Publication date: September 3, 2009
    Applicant: AstraZeneca AB
    Inventor: Gary Peter Tomkinson
  • Derivatives of isothiazol-3(2)-one 1,1-dioxides as liver X receptor modulators
    Patent number: 7582629
    Abstract: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) ? (NR1H3) and/or ? (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 9, 2006
    Date of Patent: September 1, 2009
    Assignee: AstraZeneca AB
    Inventors: Jonas Boström, Kay Brickmann, Anders Broo, Robert Judkins, Lanna Li, Pernilla Sandberg, Marianne Swanson, Christer Westerlund, Patrik Holm
  • Pyrimidyl sulphone amide derivatives as chemokine receptor modulators
    Patent number: 7582644
    Abstract: A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer.
    Type: Grant
    Filed: July 23, 2003
    Date of Patent: September 1, 2009
    Assignee: AstraZeneca AB
    Inventors: Mark Ebden, Premji Meghani, Colin Bennion, Anthony Ronald Cook, Roger Victor Bonnert
  • Solid Formulations
    Publication number: 20090215744
    Abstract: The present invention is directed to solid formulations of the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as preparations, and pharmaceutical uses thereof.
    Type: Application
    Filed: November 18, 2006
    Publication date: August 27, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Dan B. Brown, Daniel Korey, Karen B. Main, Richard J.R. Creekmore